Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Serotonin Uptake Inhibitors | 6 | 2020 | 1428 | 0.730 |
Why?
|
| Prenatal Exposure Delayed Effects | 4 | 2020 | 2277 | 0.550 |
Why?
|
| Pregnancy Complications | 11 | 2019 | 2784 | 0.460 |
Why?
|
| Antidepressive Agents | 10 | 2020 | 2728 | 0.450 |
Why?
|
| Psychotropic Drugs | 4 | 2019 | 903 | 0.360 |
Why?
|
| Depression | 5 | 2016 | 6428 | 0.330 |
Why?
|
| Depression, Postpartum | 3 | 2005 | 261 | 0.320 |
Why?
|
| Psychotherapy | 3 | 2003 | 1487 | 0.290 |
Why?
|
| Bupropion | 1 | 2005 | 295 | 0.260 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2002 | 355 | 0.240 |
Why?
|
| Depressive Disorder | 7 | 2019 | 3871 | 0.230 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2005 | 517 | 0.230 |
Why?
|
| Antimanic Agents | 2 | 2019 | 521 | 0.220 |
Why?
|
| Pregnancy | 13 | 2020 | 24529 | 0.180 |
Why?
|
| Mood Disorders | 2 | 2010 | 1079 | 0.180 |
Why?
|
| Puerperal Disorders | 2 | 2000 | 267 | 0.160 |
Why?
|
| Drug Labeling | 1 | 2018 | 251 | 0.150 |
Why?
|
| Antipsychotic Agents | 3 | 2019 | 2966 | 0.140 |
Why?
|
| Reproduction | 1 | 2018 | 658 | 0.130 |
Why?
|
| Perimenopause | 1 | 2011 | 110 | 0.110 |
Why?
|
| Bipolar Disorder | 3 | 2019 | 4894 | 0.100 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 2019 | 564 | 0.100 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1612 | 0.100 |
Why?
|
| Risk | 3 | 2016 | 9831 | 0.100 |
Why?
|
| Influenza A virus | 1 | 1992 | 425 | 0.100 |
Why?
|
| Spleen | 1 | 1992 | 2593 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1992 | 1928 | 0.080 |
Why?
|
| Estradiol | 2 | 2011 | 2000 | 0.070 |
Why?
|
| Sudden Infant Death | 1 | 2007 | 281 | 0.070 |
Why?
|
| Postpartum Period | 1 | 2010 | 845 | 0.070 |
Why?
|
| Affect | 1 | 2011 | 1446 | 0.060 |
Why?
|
| Mianserin | 1 | 2001 | 55 | 0.060 |
Why?
|
| Female | 19 | 2020 | 363115 | 0.060 |
Why?
|
| Cyclohexanols | 1 | 2001 | 134 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2004 | 437 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 1992 | 2684 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2011 | 6369 | 0.050 |
Why?
|
| Abortion, Spontaneous | 1 | 2003 | 445 | 0.050 |
Why?
|
| Depressive Disorder, Major | 2 | 2007 | 4054 | 0.050 |
Why?
|
| Mental Disorders | 1 | 2019 | 6158 | 0.050 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2002 | 470 | 0.050 |
Why?
|
| Humans | 19 | 2020 | 655361 | 0.050 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2019 | 85 | 0.050 |
Why?
|
| Recurrence | 4 | 2006 | 8024 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2005 | 2015 | 0.040 |
Why?
|
| Fluoxetine | 1 | 2002 | 765 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2007 | 2427 | 0.040 |
Why?
|
| Lithium | 1 | 2000 | 608 | 0.040 |
Why?
|
| Family Practice | 1 | 1999 | 502 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2019 | 482 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2003 | 1439 | 0.040 |
Why?
|
| Hormone Replacement Therapy | 1 | 2001 | 708 | 0.040 |
Why?
|
| Sleep | 1 | 2011 | 3598 | 0.040 |
Why?
|
| Postpartum Hemorrhage | 1 | 2019 | 231 | 0.040 |
Why?
|
| Arsenicals | 1 | 1993 | 126 | 0.030 |
Why?
|
| Nucleoproteins | 1 | 1992 | 106 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2005 | 7561 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2002 | 7457 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 11586 | 0.030 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1990 | 53 | 0.030 |
Why?
|
| Adult | 10 | 2011 | 205160 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 1993 | 885 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 1992 | 2010 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2011 | 683 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 1993 | 953 | 0.020 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2011 | 739 | 0.020 |
Why?
|
| Hot Flashes | 1 | 2011 | 289 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 1993 | 1130 | 0.020 |
Why?
|
| Risk Assessment | 4 | 2010 | 22761 | 0.020 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 15891 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2006 | 46498 | 0.020 |
Why?
|
| Risk Factors | 4 | 2004 | 66417 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2007 | 23096 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1992 | 971 | 0.020 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 1529 | 0.020 |
Why?
|
| Epitopes | 1 | 1993 | 2655 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 2019 | 2476 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1990 | 1575 | 0.020 |
Why?
|
| Viral Proteins | 1 | 1992 | 1986 | 0.020 |
Why?
|
| Parity | 1 | 2007 | 838 | 0.020 |
Why?
|
| Virus Replication | 1 | 1992 | 2560 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 1990 | 1699 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2019 | 4090 | 0.020 |
Why?
|
| Prevalence | 1 | 1999 | 14127 | 0.020 |
Why?
|
| Hypnotics and Sedatives | 1 | 2011 | 1065 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 1993 | 14610 | 0.020 |
Why?
|
| Medroxyprogesterone | 1 | 2001 | 34 | 0.020 |
Why?
|
| Causality | 1 | 2007 | 1052 | 0.010 |
Why?
|
| Withholding Treatment | 1 | 2006 | 582 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1993 | 19491 | 0.010 |
Why?
|
| Pyridines | 1 | 2011 | 2730 | 0.010 |
Why?
|
| Middle Aged | 3 | 2011 | 209591 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2011 | 11519 | 0.010 |
Why?
|
| Cell Line | 1 | 1992 | 17037 | 0.010 |
Why?
|
| Adolescent | 1 | 2005 | 82134 | 0.010 |
Why?
|
| Treatment Outcome | 3 | 2011 | 58776 | 0.010 |
Why?
|
| Time Factors | 2 | 2010 | 41724 | 0.010 |
Why?
|
| Macrophages | 1 | 1990 | 5640 | 0.010 |
Why?
|
| Menopause | 1 | 2001 | 1417 | 0.010 |
Why?
|
| Hemagglutinins, Viral | 1 | 1993 | 71 | 0.010 |
Why?
|
| Age of Onset | 1 | 2000 | 3273 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 5184 | 0.010 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1993 | 138 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1993 | 410 | 0.010 |
Why?
|
| United States | 1 | 2018 | 62666 | 0.010 |
Why?
|
| Mice | 3 | 1993 | 79101 | 0.010 |
Why?
|
| Mycobacterium avium | 1 | 1990 | 26 | 0.010 |
Why?
|
| Toxoplasmosis, Animal | 1 | 1990 | 16 | 0.010 |
Why?
|
| Legionella | 1 | 1990 | 32 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1993 | 656 | 0.010 |
Why?
|
| Arsenic | 1 | 1993 | 292 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 2001 | 2512 | 0.010 |
Why?
|
| Smoking | 1 | 2007 | 8879 | 0.010 |
Why?
|
| Receptors, Fc | 1 | 1993 | 520 | 0.010 |
Why?
|
| Orthomyxoviridae | 1 | 1990 | 137 | 0.010 |
Why?
|
| Toxoplasma | 1 | 1990 | 153 | 0.010 |
Why?
|
| Listeriosis | 1 | 1990 | 154 | 0.010 |
Why?
|
| Chagas Disease | 1 | 1990 | 147 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2004 | 12788 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1993 | 1311 | 0.010 |
Why?
|
| Trypanosoma cruzi | 1 | 1990 | 194 | 0.010 |
Why?
|
| Listeria monocytogenes | 1 | 1990 | 250 | 0.010 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1993 | 1622 | 0.010 |
Why?
|
| Male | 2 | 2018 | 341990 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2007 | 62475 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2000 | 10566 | 0.000 |
Why?
|
| Animals | 3 | 1993 | 168394 | 0.000 |
Why?
|
| Cohort Studies | 1 | 2007 | 36933 | 0.000 |
Why?
|
| Transfection | 1 | 1993 | 6405 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1993 | 3964 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1993 | 6744 | 0.000 |
Why?
|
| Base Sequence | 1 | 1993 | 13784 | 0.000 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1993 | 4231 | 0.000 |
Why?
|
| DNA | 1 | 1993 | 7317 | 0.000 |
Why?
|
Concepts
(134)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(12)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_